Hepatic Decompensation

Among veterans with chronic hepatitis B virus infection, rates of hepatitis D virus testing were low and those with concurrent infection were at greater risk for cirrhosis and hepatic decompensation, according to study results.

SAN DIEGO — The ANALI score, a magnetic resonance-based risk stratification, was associated with baseline markers of liver fibrosis in patients with primary sclerosing cholangitis, with scores linked to risk for clinical events.

Sodium-glucose cotransporter-2 inhibitors showed similar hepatic effectiveness to glucagon-like peptide-1 receptor agonists, especially among women and younger patients, in metabolic dysfunction-associated steatotic liver disease.

An FDA advisory committee voted against approval for obeticholic acid in primary biliary cholangitis without cirrhosis or compensated cirrhosis with portal hypertension, citing “concern for real possible harm”.

Tenofovir alafenamide was safe and maintained virological response in patients with chronic hepatitis B virus infection and renal or hepatic impairment who switched from tenofovir disoproxil fumarate or other antivirals, according to data.

Over 2 years, bulevirtide monotherapy reduced the risk for decompensation and mortality, but not hepatocellular carcinoma, among patients with hepatitis D virus and compensated cirrhosis compared with untreated patients.

Madrigal Pharmaceutical’s Rezdiffra received accelerated FDA approval for the treatment of patients with metabolic dysfunction-associated steatohepatitis with moderate-to-advanced fibrosis, according to a company release.

The risk for hepatic decompensation and hepatocellular carcinoma remained constant after hepatitis C virus cure among patients with advanced chronic liver disease, underscoring the need for post-HCV risk stratification in the long term.